Table 2—

Comparison of glucose and insulin response to a test meal and nateglinide, glibenclamide, or placebo in the 15 patients with MODY3 patients

NateglinideP1GlibenclamideP2PlaceboP3
Plasma glucose (mmol/l)
    Fasting7.9 (5.6)NS7.8 (2.2)NS7.8 (2.7)NS
    Peak9.8 (8.9)0.03111.5 (6.6)0.03112.7 (7.2)<0.0001
    140 min9.1 (7.8)0.0297.1 (9.2)0.000110.4 (9.9)0.0038
    170 min7.3 (7.0)0.0046.3 (8.0)*0.00058.3 (10.3)0.0018
    260 min6.4 (4.9)0.0065.5 (3.9)0.00027.6 (7.8)0.0124
    ΔPeak3.3 (2.9)0.0314.5 (3.9)NS4.7 (3.5)<0.0001
    Δ140 min1.85 (2.85)0.026−0.3 (5.6)0.00192.7 (4.7)0.0008
    AUC140 min§101 (294)0.041186 (391)0.027250 (348)<0.0001
Urine glucose (mmol/l)
    Fasting0 (20.4)NS1.4 (37.1)NS(21.3)NS
    140 min15.4 (59.8)NS42.7 (74.0)NS33.0 (97.0)NS (0.06)
    260 min3.8 (52.8)NS10.4 (70.1)NS46.0 (67.9)NS
    Serum insulin (mU/l)
    Fasting5.8 (4.3)NS5.2 (4.5)NS6.0 (5.4)NS
    Peak47.0 (26.0)0.02380.4 (71.7)0.000233.7 (24.9)<0.001
    AUC140 min§2,912 (1,668)0.0243,253 (3,888)0.00021,652 (2,150)0.002
Hypoglycemia (n)0/150.0306/150.0300/15NS
  • Data are median (interquartile range). Each patient participated in the test three times receiving in double-blind random order: 1) placebo at time 0 min and 30 mg nateglinide at 20 min, 2) 1.25 mg glibenclamide at 0 min and placebo at 20 min, or 3) placebo at both 0 and 20 min. The subjects ingested a test meal between 30 and 45 min. P1: nateglinide vs. glibenclamide visits; P2: glibenclamide vs. placebo visits; P3: nateglinide vs. placebo visits.

  • *

    * n = 14 and

  • n = 12 due to hypoglycemia.

  • Difference between peak or 140 min glucose and fasting glucose.

  • §

    § AUC, incremental area under the curve during 0–140 min.

  • Plasma glucose ≤3.5 mmol/l.